Beaufour Ipsen: Gearing up to Go Public
Family-owned Beaufour Ipsen has kept its cards to its chest for most of its 70-year history. Now, though, France's third largest independent pharmaceutical company is gearing up for a big US push-and to go public.
You may also be interested in...
Recent Big Pharma deals validate Pierre Fabre's productive research, and underline mid-sized pharmas' importance as a product source. But the French group hasn't yet fully capitalized on its R&D.
Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.
Europe's financing and regulatory environment means that it has been, and will continue to be, very difficult to build Amgen-style big biotech from scratch here. But a sustainable industry of large biotechs is nevertheless emerging-mostly through the transformation of existing big or mid-sized pharma assets. Big Pharma spin outs, created to circumvent prohibitive labor laws, and small, R&D-embracing in-licensing firms are two important sources. But so are the mid-sized drug firms--another largely European phenomenon. The potential transformation of UCB into a big biotech, triggered by the acquisition of Celltech, is the most recent example.